The regulatory roles of mitogen-activated protein kinase (MAPK) pathways in health and diabetes: Lessons learned from the pancreatic β-cell

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 10, Issue 2, 2016, Pages 76-84

  Sidarala, Vaibhav ^a   Kowluru, Anjaneyulu ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Glucotoxicity; MAPK signaling; NADPH oxidase 2; Oxidative stress; Pancreatic cell; Rac1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CYTOTOXICITY; DIABETES MELLITUS; DIABETOGENESIS; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INTRACELLULAR SIGNALING; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; MAPK SIGNALING; METABOLISM; PATENT; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PATENTS AS TOPIC; REACTIVE OXYGEN SPECIES;

EID: 85021102771     PISSN: 18722148     EISSN: 22123334     Source Type: Journal    
DOI: 10.2174/1872214810666161020154905     Document Type: Review

References (95)

1. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, et al. MAP kinases. Chem Rev 2001; 101(8): 2449-76.
2. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23(16): 2838-49.
3. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75(1): 50-83.
4. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: Structure, regulation and functions. Biochim Biophys Acta 2007; 1773(8): 1376-87.
5. Sheridan DL, Kong Y, Parker SA, Dalby KN, Turk BE. Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. J Biol Chem 2008; 283(28): 19511-20.
6. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26(22): 3100-12.
7. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12(1): 9-18.
8. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22(2): 153-83.
9. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 2006; 5(5): 14.
10. Lefloch R, Pouyssegur J, Lenormand P. Total ERK1/2 activity regulates cell proliferation. Cell Cycle 2009; 8(5): 705-11.
11. Roskoski R, Jr. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res 2012; 66(2): 105-43.
12. Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, et al. Regulation and properties of extracellular signalregulated protein kinases 1 and 2 in vitro. J Biol Chem 1993; 268(7): 5097-106.
13. Roskoski R, Jr. RAF protein-serine/threonine kinases: Structure and regulation. Biochem Biophys Res Commun 2010; 399(3): 313-7.
14. Zheng CF, Guan KL. Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. EMBO J 1994; 13(5): 1123-31.
15. Roskoski R, Jr. MEK1/2 dual-specificity protein kinases: Structure and regulation. Biochem Biophys Res Commun 2012; 417(1): 5-10.
16. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008; 13: 4258-75.
17. Viala E, Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann NY Acad Sci 2004; 1030: 208-18.
18. Wolf I, Rubinfeld H, Yoon S, Marmor G, Hanoch T, Seger R. Involvement of the activation loop of ERK in the detachment from cytosolic anchoring. J Biol Chem 2001; 276(27): 24490-7.
19. Babu GJ, Lalli MJ, Sussman MA, Sadoshima J, Periasamy M. Phosphorylation of ELK-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. J Mol Cell Cardiol 2000; 32(8): 1447-57.
20. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072(2-3): 129-57.
21. Whitmarsh AJ. Regulation of gene transcription by mitogenactivated protein kinase signaling pathways. Biochim Biophys Acta 2007; 1773(8): 1285-98.
22. Kalwat MA, Thurmond DC. Signaling mechanisms of glucoseinduced F-actin remodeling in pancreatic islet beta cells. Exp Mol Med 2013; 45: e37.
23. Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, Dong C, et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci USA 2003; 100(25): 15184-9.
24. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev 2010; 90(4): 1507-46.
25. Antoniou X, Falconi M, Di Marino D, Borsello T. JNK3 as a therapeutic target for neurodegenerative diseases. J Alzheimers Dis 2011; 24(4): 633-42.
26. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev 2012; 92(2): 689-737.
27. Iriyama T, Takeda K, Nakamura H, Morimoto Y, Kuroiwa T, Mizukami J, et al. ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis. EMBO J 2009; 28(7): 843-53.
28. Craige SM, Reif MM, Kant S. Mixed -Lineage Protein Kinases (MLKs) in inflammation, metabolism, and other disease states. Biochim Biophys Acta 2016; 1862(9): 1581-6.
29. Lee HS, Hwang CY, Shin SY, Kwon KS, Cho KH. MLK3 is part of a feedback mechanism that regulates different cellular responses to reactive oxygen species. Sci Signal 2014; 7(328): ra52.
30. Humphrey RK, Ray A, Gonuguntla S, Hao E, Jhala US. Loss of TRB3 alters dynamics of MLK3-JNK signaling and inhibits cytokine-activated pancreatic beta cell death. J Biol Chem 2014; 289(43): 29994-30004.
31. Sharma M, Urano F, Jaeschke A. Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. J Hepatol 2012; 56(1): 192-8.
32. Fleming Y, Armstrong CG, Morrice N, Paterson A, Goedert M, Cohen P. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogenactivated protein kinase kinase 4 (MKK4) and MKK7. Biochem J 2000; 352(Pt 1): 145-54.
33. Li L, Feng Z, Porter AG. JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells. J Biol Chem 2004; 279(6): 4058-65.
34. Bogoyevitch MA, Kobe B. Uses for JNK: The many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006; 70(4): 1061-95.
35. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002; 277(12): 10244-50.
36. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27(48): 6245-51.
37. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277(2): 1531-7.
38. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420(6913): 333-6.
39. del Barco Barrantes I, Coya JM, Maina F, Arthur JS, Nebreda AR. Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during mouse development. Proc Natl Acad Sci USA 2011; 108(31): 12764-9.
40. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773(8): 1358-75.
41. Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal 2013; 8(1): 7.
42. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007; 11(2): 191-205.
43. Teramoto H, Coso OA, Miyata H, Igishi T, Miki T, Gutkind JS. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J Biol Chem 1996; 271(44): 27225-8.
44. Zhou F, Xu Y, Hou XY. MLK3-MKK3/6-P38MAPK cascades following N-methyl-D-aspartate receptor activation contributes to amyloid-beta peptide-induced apoptosis in SH-SY5Y cells. J Neurosci Res 2014; 92(6): 808-17.
45. Sidarala V, Veluthakal R, Syeda K, Vlaar C, Newsholme P, Kowluru A. Phagocyte-like NADPH oxidase (Nox2) promotes activation of p38MAPK in pancreatic beta-cells under glucotoxic conditions: Evidence for a requisite role of Ras-related C3 botulinum toxin substrate 1 (Rac1). Biochem Pharmacol 2015; 95(4): 301-10.
46. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9(8): 537-49.
47. Trempolec N, Dave-Coll N, Nebreda AR. SnapShot: p38 MAPK substrates. Cell 2013; 152(4): 924-e1.
48. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005; 15(1): 11-8.
49. Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013; 4(9-10): 342-59.
50. Teodoro T, Odisho T, Sidorova E, Volchuk A. Pancreatic beta-cells depend on basal expression of active ATF6alpha-p50 for cell survival even under nonstress conditions. Am J Physiol Cell Physiol 2012; 302(7): C992-1003.
51. Luo S, Lee AS. Requirement of the p38 mitogen-activated protein kinase signalling pathway for the induction of the 78 kDa glucoseregulated protein/immunoglobulin heavy-chain binding protein by azetidine stress: Activating transcription factor 6 as a target for stress-induced phosphorylation. Biochem J 2002; 366(Pt 3): 787-95.
52. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18(23): 6845-54.
53. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 1998; 273(49): 33048-53.
54. Loughery J, Cox M, Smith LM, Meek DW. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res 2014; 42(12): 7666-80.
55. Schieven GL. The biology of p38 kinase: A central role in inflammation. Curr Top Med Chem 2005; 5(10): 921-8.
56. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 1998; 273(42): 27467-73.
57. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004; 53(Suppl 3): S16-21.
58. Wahren J, Kallas A. Loss of pulsatile insulin secretion: A factor in the pathogenesis of type 2 diabetes? Diabetes 2012; 61(9): 2228-9.
59. Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801(3): 289-98.
60. Kowluru A, Kowluru RA. Phagocyte-like NADPH oxidase [Nox2] in cellular dysfunction in models of glucolipotoxicity and diabetes. Biochem Pharmacol 2014; 88(3): 275-83.
61. Veluthakal R, Sidarala V, Kowluru A. NSC23766, a known inhibitor of Tiam1-Rac1 signaling module, prevents the onset of type 1 diabetes in the NOD mouse model. Cell Physiol Biochem 2016; 39(2): 760-7.
62. Syed I, Jayaram B, Subasinghe W, Kowluru A. Tiam1/Rac1 signaling pathway mediates palmitate-induced, ceramide-sensitive generation of superoxides and lipid peroxides and the loss of mitochondrial membrane potential in pancreatic beta-cells. Biochem Pharmacol 2010; 80(6): 874-83.
63. Sidarala V, Veluthakal R, Syeda K, Kowluru A. EHT 1864, a small molecule inhibitor of Ras-related C3 botulinum toxin substrate 1 (Rac1), attenuates glucose-stimulated insulin secretion in pancreatic beta-cells. Cell Signal 2015; 27(6): 1159-67.
64. Veluthakal R, Tunduguru R, Arora DK, Sidarala V, Syeda K, Vlaar CP, et al. VAV2, a guanine nucleotide exchange factor for Rac1, regulates glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia 2015; 58(11): 2573-81.
65. Asahara S, Shibutani Y, Teruyama K, Inoue HY, Kawada Y, Etoh H, et al. Ras-related C3 botulinum toxin substrate 1 (RAC1) regulates glucose-stimulated insulin secretion via modulation of F-actin. Diabetologia 2013; 56(5): 1088-97.
66. Taylor-Fishwick DA. NOX, NOX who is there? The contribution of NADPH oxidase one to beta cell dysfunction. Front Endocrinol (Lausanne) 2013; 4: 40.
67. Newsholme P, Morgan D, Rebelato E, Oliveira-Emilio HC, Procopio J, Curi R, et al. Insights into the critical role of NADPH oxidase( s) in the normal and dysregulated pancreatic beta cell. Diabetologia 2009; 52(12): 2489-98.
68. Lawrence M, Shao C, Duan L, McGlynn K, Cobb MH. The protein kinases ERK1/2 and their roles in pancreatic beta cells. Acta Physiol (Oxf) 2008; 192(1): 11-7.
69. Frodin M, Sekine N, Roche E, Filloux C, Prentki M, Wollheim CB, et al. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting betacell line, INS-1. J Biol Chem 1995; 270(14): 7882-9.
70. Benes C, Roisin MP, Van Tan H, Creuzet C, Miyazaki J, Fagard R. Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line. J Biol Chem 1998; 273(25): 15507-13.
71. Benes C, Poitout V, Marie JC, Martin-Perez J, Roisin MP, Fagard R. Mode of regulation of the extracellular signal-regulated kinases in the pancreatic beta-cell line MIN6 and their implication in the regulation of insulin gene transcription. Biochem J 1999; 340 (Pt 1): 219-25.
72. Longuet C, Broca C, Costes S, Hani EH, Bataille D, Dalle S. Extracellularly regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phosphorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of Langerhans. Endocrinology 2005; 146(2): 643-54.
73. Arnette D, Gibson TB, Lawrence MC, January B, Khoo S, McGlynn K, et al. Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem 2003; 278(35): 32517-25.
74. Trumper J, Ross D, Jahr H, Brendel MD, Goke R, Horsch D. The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells. Diabetologia 2005; 48(8): 1534-40.
75. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010; 285(44): 33623-31.
76. Yeo RW, Yang K, Li G, Lim SK. High glucose predisposes gene expression and ERK phosphorylation to apoptosis and impaired glucose-stimulated insulin secretion via the cytoskeleton. PLoS One 2012; 7(9): e44988.
77. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cellpermeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 2001; 50(1): 77-82.
78. Hyöty H, Taylor KW. The role of viruses in human diabetes. Diabetologia 2002; 45(10): 1353-61.
79. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes. Diabetes 2008; 57(11): 2863-71.
80. Peng H, Shi M, Zhang L, Li Y, Sun J, Zhang L, et al. Activation of JNK1/2 and p38 MAPK signaling pathways promotes enterovirus 71 infection in immature dendritic cells. BMC Microbiol 2014; 14: 147.
81. Si X, Luo H, Morgan A, Zhang J, Wong J, Yuan J, et al. Stressactivated protein kinases are involved in coxsackievirus B3 viral progeny release. J Virol 2005; 79(22): 13875-81.
82. Syed I, Kyathanahalli CN, Jayaram B, Govind S, Rhodes CJ, Kowluru RA, et al. Increased phagocyte-like NADPH oxidase and ROS generation in type 2 diabetic ZDF rat and human islets: Role of Rac1-JNK1/2 signaling pathway in mitochondrial dysregulation in the diabetic islet. Diabetes 2011; 60(11): 2843-52.
83. Kawamori D, Kajimoto Y, Kaneto H, Umayahara Y, Fujitani Y, Miyatsuka T, et al. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH(2)-terminal kinase. Diabetes 2003; 52(12): 2896-904.
84. Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y, Tamaki T. Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin 2004; 25(8): 977-85.
85. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Tamaki T. Antioxidants inhibit JNK and p38 MAPK activation but not ERK 1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res 2001; 24(3): 251-61.
86. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54(Suppl 2): S97-107.
87. Combette, J.M., Deloche, C. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases. WO2016055160 (2016).
88. Bonny, C. Cell-permeable peptide inhibitors of the JNK signal transduction pathway. EP1911458 (2014).
89. Wang, B.H., Krum, H., Scammells, P., Vinh, N., Simpson, J., Chalmers D. Inhibitors of MAPK. WO2016029263 (2016).
90. Goodfellow, V.S., Nguyen, T.X., Ravula, S.B., Gelbard, H.A. Mixed lineage kinase inhibitors and method of treatments. US20140256733 (2014).
91. Oommen, A.M., Verma, M.K., Bahadur, U., Ramu, S. Use of TAK-1 inhibitor to achieve glycemic control in mammals. US20140154263 (2014).
92. Ranayhossaini, D.J., Pagano, P.J. Novel inhibitors of Nox1. US20160089414 (2016).
93. Taylor-Fishwick, D. Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting Nox-1. WO2014153227 (2014).
94. Kim, D.J., Jung, N.Y. Pharmaceutical composition having antidiabetic and antiobesity activities. W02014017787 (2014).
95. Antinozzi, P.A., Dover, E.N. Compositions and methods for maintaining and improving pancreatic islet cell function and stability. WO2014117080 (2014).